<SEC-DOCUMENT>0001193125-23-001140.txt : 20230104
<SEC-HEADER>0001193125-23-001140.hdr.sgml : 20230104
<ACCEPTANCE-DATETIME>20230104060600
ACCESSION NUMBER:		0001193125-23-001140
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221223
FILED AS OF DATE:		20230104
DATE AS OF CHANGE:		20230104

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		23504285

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d382515d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated December 23, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 33, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form 40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the
registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant
is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><A HREF="d382515dex991.htm">Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: December 23, 2022 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d382515dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g382515dedededede.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha&#146;s
potential to address high unmet need for metastatic breast cancer patients </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Patient population expanded to include patients with triple-negative breast cancer </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Late-stage clinical development efforts remain focused on frontline
<FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC) in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Immutep&#146;s cash runway extended to the end of the 1st half of calendar year 2024 </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 23</B><B></B><B>&nbsp;December 2022 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or &#147;the
Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces the results of a positive
<FONT STYLE="white-space:nowrap">follow-up</FONT> Type C meeting with the US Food and Drug Administration (FDA) regarding late-stage clinical development plans for its
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein, eftilagimod alpha (&#147;efti&#148;), in conjunction with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy for the treatment of metastatic breast cancer (MBC). The Company and the FDA have agreed to an integrated Phase II/III trial design that will help inform a Biologics License
Application (BLA). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the encouraging efficacy, favourable safety, and learnings from the randomised AIPAC Phase IIb trial, which administered efti
and chemotherapy on different days and ceased chemotherapy at six months, patients will receive efti and paclitaxel on the same day and treatment will continue until disease progression. The patient population has also been expanded to include
triple-negative breast cancer (TNBC), an aggressive form of breast cancer with limited treatment options. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CEO, Marc Voigt, commented: &#147;As
recently announced, our late-stage clinical development efforts for efti are now focused on frontline NSCLC in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-1</FONT></FONT> therapy, given the large market
opportunity and need for more durable and tolerable options. With this said, progress reported to date with the FDA and EMA provides Immutep and its potential partners flexibility for late-stage clinical development of efti plus <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy to address the high unmet need for metastatic breast cancer patients, while maintaining their quality of life as was shown in the AIPAC
trial.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep CSO&nbsp;&amp; CMO, Dr.&nbsp;Fr&eacute;d&eacute;ric Triebel, stated: &#147;We are excited about efti&#146;s promise to stimulate the
immune system and improve <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy by activating dendritic cells to present antigens from chemo-induced cancer cell death to cytotoxic T cells. Our
engagement with regulatory agencies to establish the optimal design of a registrational trial has steadily progressed during the year and we are pleased with the FDA&#146;s positive feedback during this follow up meeting. The chosen trial design
provides us with a very risk-balanced approach before potentially embarking on the Phase 3 part of this study.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g382515dedededede.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to regulatory and ethic committee feedback, the Phase II portion of the MBC trial is expected to
begin during the first quarter of 2023. In addition to the biologically active 30mg dosing for efti, the Company and FDA have agreed to test 90mg efti dosing in combination with paclitaxel driven predominantly by the excellent safety profile of the
AIPAC Phase IIb trial, along with the <U>FDA&#146;s Project Optimus</U> initiative in oncology. The trial design has a safety lead in of 6 to 12 patients, given the higher 90mg dosing of efti, followed by 58 patients for the randomised Phase II
portion of the trial. Depending on Phase II results and resources, the Phase III portion will follow and be directed to MBC patients most likely to benefit from treatment, taking into consideration the strong overall survival results in <FONT
STYLE="white-space:nowrap">pre-specified</FONT> and <FONT STYLE="white-space:nowrap">post-hoc</FONT> subgroups from the AIPAC trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Phase II portion
of the MBC trial and the initiation of the registrational trial in 1st line NSCLC are included in the budget of the Company and have no impact on its expected cash runway to the end of the 1st half of calendar year 2024. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alpha (Efti) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s
proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> clinical stage candidate that is a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator for the
treatment of cancer, capitalising on <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> unique characteristics to stimulate both innate and adaptive immunity. Efti binds to and activates antigen presenting cells via MHC II molecules leading to
expansion and proliferation of CD8+ (cytotoxic) T cells, CD4+ (helper) T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like CXCL10 that further boost the immune system&#146;s ability
to fight cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer
(NSCLC), head and neck squamous cell carcinoma (HNSCC), and HER2&#150;/HR+ metastatic breast cancer. Its favourable safety profile enables various combinations, including with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track Designation in 1st line HNSCC and in 1st line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
clinical stage biotechnology company leading the development of <FONT STYLE="white-space:nowrap">LAG-3</FONT> related immunotherapy products for the treatment of cancer and autoimmune disease. The Company is dedicated to leveraging its technology
and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s lead product candidate
is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> fusion protein <FONT STYLE="white-space:nowrap">(LAG-3Ig),</FONT> which is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator being explored in cancer in multiple clinical trials. The Company is also developing an agonist of <FONT STYLE="white-space:nowrap">LAG-3</FONT> (IMP761)
for autoimmune disease. Additional <FONT STYLE="white-space:nowrap">LAG-3</FONT> product candidates, including antibodies for immune response modulation, are being developed under license by Immutep&#146;s large pharmaceutical partners. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information can be found on the Company&#146;s website <U>www.immutep.com</U> or by contacting: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>cstrong@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tim McCarthy, LifeSci Advisors </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917) 679 9282; <U>tim@lifesciadvisors.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g382515dedededede.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g382515dedededede.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 =/;]* /D3PO^U#-XA^-=S\+6\(&UTS^VM9\/V>JI>R2:DMYHJWADO+V
MQ^SB-+.4V,ORI)NB61&9GP10!]=T % !0 4 % !0 4 % !0 4 % !0 4 <%X
MG^*/P[\%W/V'Q1XQT'1K]4BD_LZZOHSJ(CF_U+_8(M]QL<?=/EX...E '=JP
M=593E64,IZ9##(.#[&@!U !0 4 % !0 =/PHV^0;?(_-+XD^"]=T;XL7^E6-
MJSW6N:X=7\.,2B178U"[:\AVRS,L>8+HR12;F !A.>&&?E,50J4L;*$5K4GS
M4^B=W=?<]S\DS;+L3A\[J4:4&YXFM[6AT4^>7.M79>[+FC+LUYJ_MWBS]I%K
M"QU'PT?"[2>(X(7TC59YKQ8M(6]$ M]4>U6W+7$D(F,XBR8SC:Q/8^A6S7EC
M*E[%NK%<LFVN6]K.UKMZ[;'T6.XM]C3JX3ZFY8N"]G4;DE2Y^6U3EM>;2E=1
MVZ,\1^%OABU\3_$SPU#X;@U1=)TB;3-<U674C \MG_9ABN+D&:U14\B6_2."
M#< ["3+#AL>?@Z*JXNC[)24*?+.7-;3E=WJM+-Z(^=R;!T\9G&$6"C4^KX=T
MZU1U+-P]G9M7CI:4THPOJUJ]F?I:./P_2OJ]OD?K>WR"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MA0=VH ]S\5>#/#/CS3(;76K1;N)"+K3=0M)C!?6,CJK)=:;?P'=$678>"R.
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MWLMS9)BM;JSNE3)^6.>.,86-0#] _0^T: "@ H * "@ H * "@ H * "@ H
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M &5/^1UUSV\*O^'_ !--.KP<FTQ%7RI+_P!*1\!P3_O^*\L,O_3D#G_VA_\
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MW-SH>C6KD$)-<6,=]>7@4]#Y:7UF#Z&7% 'Z!4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * ,K1M7M
M];T^/4K5)HX))[ZW59U5) ]A?7.GRDJCL-K36LA7GE2I(!)  ,[2?%>F:QK.
MM:':K<K<Z(Z*\TT2QVM^H>2VNY=-DWDW,=GJ$,UE<$JOESQ%>0RLP!#IOBA]
M7NC_ &9HFHW&C+>W=A_;YFTR"S>:QFFM;F:WMIKY;N>R2[@E@$RP?.R%HU>+
M$A -[4+J>RLY;BUL9=0FCV[+2&:TMG?<ZJS&:]GBBCC1278E\[4.T,V 0"IX
M?UJ#Q#I5OJMM!/;1SR7<+07/E&6&>PO+BPN4\RWEEAFC%S;2[)H9)(Y$VR(Q
M5P: ,;4O&^F:5I/B/6)[74I;?PQJL>D7D%I;I/=W%S+_ &6$^PP+*#."=6M@
M%RKDJX52=NX LR^,-&36O#NAPR2W=SXFL[C4-/GM$66SCLH+.2]AN+J?>!"E
MU##/]GP&,IMIL#$3$ %2'Q[H,B>+6=KJ#_A#+F6WU1)H,23JD9,5QIJ*S&]@
MFN4N+.+;AFN;2:';N4;@"W8>+-/OX_"DD4%Y&/%VFR:GIRRQQH]M%%80:@\5
M\HE/E3K%<*A6/S!O1AG !(!1U#QYI.F:5<ZQ<6NIM:V?B4^%YTMK47-P+M=2
M&FRW26\4A>6SC<M*Q0-+Y4;%8V8!2 :9\5Z,C:PSW 6RT/1=/\07FI I)8MI
M>HQ:E/#<V\D+.TRK!I<[G:N"'CV%MW !1LO%S2WFEVNIZ!K&A1ZZSQ:-=:B=
M.>.ZN$M);Y;*ZCLKZ>33;Z2RM[B9(KA%!%O(A82KY9 'V/BB[O-?N] ;PUJM
MI)80V5U=WDUWHCVD5IJ,FI16,X6WU22>3S'TNY!18BR90L!G@ D3Q?ICZ=;:
MD$N!%<^(O^$:2'$/GK??\)%)X:\UD\[ MOML329!+>5AMN[Y: "/Q.\^O7^A
MVFC7]PNE7EE8W^HBZTF&UAEO=/M-35D@GU!+J>..UO82QCMV.[<JAMM %*[\
M<6]E?:C!+H^J'3=(UK2] O\ 6HVTYK2WU'5H=)EM,VIOQ>26H;6]/C>6.W;:
MTC':41G !I:UXKTW0=2T33+Q;EIM:N?(26"-9(-/C,MO:0W>I.7!MK2;4[W3
M[&-P'+3WT0P$#O& 0:SXJ.E:D=,M]$U36)X-)?6[HV$FF1+;V"7#VWRC4=0M
MC/<%XY"(X\\+UR0" 12>.="ABANIGN(+"[\-)XITV^DBVP:EI^(WF@LUW>:^
MI11W-@QM6C5V%_"(]Y#B, XGX[3/<? SXA3R6\MH\_@Z\F>UGV>?;/)#&[03
M>4[IYT98HVQV7<IPQ&"0#Y1_82_Y"'Q*_P"O/PM_Z/UV@#]%J "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MZB@#R'X!? .Y^"ESXGGG\3P>(1XAATJ%%ATF33/LG]F/?N68OJ%SYWF?;0
M$V^7WSP;!L?25 !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 ?(_\ PUCI/_0EZG_X-K3_ .1:\7^V8?\
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MP_\ D0_X:QTG_H2]3_\ !M:?_(M']LP_Z!Y?^!+_ "#_ %WH?]"^I_X-A_\
M(A_PUCI/_0EZG_X-K3_Y%H_MF'_0/+_P)?Y!_KO0_P"A?4_\&P_^1#_AK'2?
M^A+U/_P;6G_R+1_;,/\ H'E_X$O\@_UWH?\ 0OJ?^#8?_(A_PUCI/_0EZG_X
M-K3_ .1:/[9A_P! \O\ P)?Y!_KO0_Z%]3_P;#_Y$/\ AK'2?^A+U/\ \&UI
M_P#(M']LP_Z!Y?\ @2_R#_7>A_T+ZG_@V'_R(?\ #6.D_P#0EZG_ .#:T_\
MD6C^V8?] \O_  )?Y!_KO0_Z%]3_ ,&P_P#D0_X:QTG_ *$O4_\ P;6G_P B
MT?VS#_H'E_X$O\@_UWH?]"^I_P"#8?\ R(?\-8Z3_P!"7J?_ (-K3_Y%H_MF
M'_0/+_P)?Y!_KO0_Z%]3_P &P_\ D0_X:QTG_H2]3_\ !M:?_(M']LP_Z!Y?
M^!+_ "#_ %WH?]"^I_X-A_\ (A_PUCI/_0EZG_X-K3_Y%H_MF'_0/+_P)?Y!
M_KO0_P"A?4_\&P_^1#_AK'2?^A+U/_P;6G_R+1_;,/\ H'E_X$O\@_UWH?\
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MP_\ D0_X:QTG_H2]3_\ !M:?_(M']LP_Z!Y?^!+_ "#_ %WH?]"^I_X-A_\
M(A_PUCI/_0EZG_X-K3_Y%H_MF'_0/+_P)?Y!_KO0_P"A?4_\&P_^1#_AK'2?
M^A+U/_P;6G_R+1_;,/\ H'E_X$O\@_UWH?\ 0OJ?^#8?_(A_PUCI/_0EZG_X
M-K3_ .1:/[9A_P! \O\ P)?Y!_KO0_Z%]3_P;#_Y$/\ AK'2?^A+U/\ \&UI
M_P#(M']LP_Z!Y?\ @2_R#_7>A_T+ZG_@V'_R(?\ #6.D_P#0EZG_ .#:T_\
MD6C^V8?] \O_  )?Y!_KO0_Z%]3_ ,&P_P#D0_X:QTG_ *$O4_\ P;6G_P B
MT?VS#_H'E_X$O\@_UWH?]"^I_P"#8?\ R(?\-8Z3_P!"7J?_ (-K3_Y%H_MF
M'_0/+_P)?Y!_KO0_Z%]3_P &P_\ D0_X:QTG_H2]3_\ !M:?_(M']LP_Z!Y?
M^!+_ "#_ %WH?]"^I_X-A_\ (A_PUCI/_0EZG_X-K3_Y%H_MF'_0/+_P)?Y!
M_KO0_P"A?4_\&P_^1#_AK'2?^A+U/_P;6G_R+1_;,/\ H'E_X$O\@_UWH?\
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MP_\ D0_X:QTG_H2]3_\ !M:?_(M']LP_Z!Y?^!+_ "#_ %WH?]"^I_X-A_\
M(A_PUCI/_0EZG_X-K3_Y%H_MF'_0/+_P)?Y!_KO0_P"A?4_\&P_^1#_AK'2?
M^A+U/_P;6G_R+1_;,/\ H'E_X$O\@_UWH?\ 0OJ?^#8?_(A_PUCI/_0EZG_X
M-K3_ .1:/[9A_P! \O\ P)?Y!_KO0_Z%]3_P;#_Y$/\ AK'2?^A+U/\ \&UI
M_P#(M']LP_Z!Y?\ @2_R#_7>A_T+ZG_@V'_R(?\ #6.D_P#0EZG_ .#:T_\
MD6C^V8?] \O_  )?Y!_KO0_Z%]3_ ,&P_P#D0_X:QTG_ *$O4_\ P;6G_P B
MT?VS#_H'E_X$O\@_UWH?]"^I_P"#8?\ R(?\-8Z3_P!"7J?_ (-K3_Y%H_MF
M'_0/+_P)?Y!_KO0_Z%]3_P &P_\ D0_X:QTG_H2]3_\ !M:?_(M']LP_Z!Y?
M^!+_ "#_ %WH?]"^I_X-A_\ (A_PUCI/_0EZG_X-K3_Y%H_MF'_0/+_P)?Y!
M_KO0_P"A?4_\&P_^1#_AK'2?^A+U/_P;6G_R+1_;,/\ H'E_X$O\@_UWH?\
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K?F: N^X;F_O-^9H"[[AN;^\WYF@+ON&YO[S?F: N^X;F_O-^9H"[[G__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
